已收盘 07-26 16:00:00 美东时间
-5.500
-3.77%
Morgan Stanley analyst Patrick Wood maintains TransMedics Gr (NASDAQ:TMDX) with a Equal-Weight and raises the price target from $104 to $145.
07-16 00:51
In the last three months, 9 analysts have published ratings on TransMedics Gr (...
07-15 22:01
Analyst Josh Jennings from TD Cowen maintained a Buy rating on TransMedics Grou...
07-06 04:25
If we want to find a potential multi-bagger, often there are underlying trends ...
07-03 19:38
TransMedics Gr's (NYSE:TMDX) short percent of float has risen 3.74% since its l...
07-03 03:45
NEW YORK, June 24, 2024 /PRNewswire/ -- Oldest and largest small-cap closed-en...
06-25 00:32
In a report released today, Josh Jennings from TD Cowen reiterated a Buy rating...
06-07 18:56
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is trading higher Tuesday after the company announced three-year results from the ongoing HOPE-2 open-label extension
06-05 01:12
Strong data from TransMedics' clinical trials is expected to drive adoption. Longer-term, the annual market opportunity is $1.5 billion.
06-04 23:10
Stephens initiated coverage of TransMedic (NASDAQ:TMDX) with an overweight rating, citing its Organ Care System technology for the transportation of donor organs. The investment bank said the technolo...
06-04 22:24